![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB | |
|
PDF (Supplemental Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
956kB |
| Item Type: | Article |
|---|---|
| Title: | Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron |
| Creators Name: | Kreye, J. and Reincke, S.M. and Edelburg, S. and Jeworowski, L.M. and Kornau, H.C. and Trimpert, J. and Hombach, P. and Halbe, S. and Nölle, V. and Meyer, M. and Kattenbach, S. and Sánchez-Sendin, E. and Schmidt, M.L. and Schwarz, T. and Rose, R. and Krumbholz, A. and Merz, S. and Adler, J.M. and Eschke, K. and Abdelgawad, A. and Schmitz, D. and Sander, L.E. and Janssen, U. and Corman, V.M. and Prüss, H. |
| Abstract: | The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent demand for updated therapies. We selected the patient-derived antibody CV38-142 based on its potency and breadth against the VOCs Alpha, Beta, Gamma, and Delta for preclinical development into a therapeutic. CV38-142 showed in vivo efficacy in a Syrian hamster VOC infection model after post-exposure and therapeutic application and revealed a favorable safety profile in a human protein library screen and tissue cross-reactivity study. Although CV38-142 targets the same viral surface as sotrovimab, which maintains activity against Omicron, CV38-142 did not neutralize the Omicron lineages BA.1 and BA.2. These results highlight the contingencies of developing antibody therapeutics in the context of antigenic drift and reinforce the need to develop broadly neutralizing variant-proof antibodies against SARS-CoV-2. |
| Keywords: | Animals, Hamsters |
| Source: | iScience |
| ISSN: | 2589-0042 |
| Publisher: | Cell Press |
| Volume: | 26 |
| Number: | 4 |
| Page Range: | 106323 |
| Date: | 21 April 2023 |
| Official Publication: | https://doi.org/10.1016/j.isci.2023.106323 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
